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ABSTRACT 
Cancer is characterised as a set of diseases that is involved in uncontrolled cell growth with the 
ability to invade or spread to the other part of the body. Carcinogenesis is recognized as a process 
through aggregation of genetic and epigenetic changes in normal cell that ultimately leading to 
unlimited growth proliferation and invasion. Pancreatic neuroendocrine tumour (PNET) is a rare 
tumour that arise from neuroendocrine gland, occurs in various part of the body. The prevalence 
rate of PNETs is near about 25–30 per 100,000 population in the United States and according to 
Surveillance Epidemiology and End Results (SEER), the incidence rate of PNETs increased five-fold 
from 1973 to 2011. PNETs comprises approximately 7% of all types of cancer in the pancreas. 
Normally, 5 years survival rate of PNETs near about 42%. 
PNETs is a heterogenous group of disorder with less 5 years survival rate due to lack of effective 
therapeutic options for patients with advanced stages, absence of symptomatology specially in 
case of non-functional PNETs and also to the phenomenon of chemoresistance, dependent on 
multiple mechanisms. Recent data shows that incidence rate of this tumour increases as a result 
of germline genetic mutations. Concerning to genetic change, it is very important to explain the 
differences that occurs at the level of chemoresistance. The treatment plan of the PNETs varies 
on type, location and aggressiveness of the tumour. Surgery is the only curative treatment in 
early stage but in advanced stages chemotherapy and radiotherapy are the most palliative 
treatment option of PNETs. Chemotherapy which is mainly based cisplatin combined with 
capecitabine and the response rate of treatment is near about 30%. Cisplatin is responsible for 
the formation of DNA adducts, leading to DNA damage, and induces generation of ROS, that 
consequently leads to oxidative stress, cell damage and death. Glutathione (GSH) plays an 
important role in the maintenance of intercellular redox balance and detoxification. 
Chemoresistance can be based on the alteration of the detoxification mechanisms and GSH 
system has been pointed as one of the most important. Cysteine is a rate limitant substrate for 
GSH synthesis, and xCT cyst(e)ine transporter is implicated in cancer severity and 
chemoresistance.  
The Hypothesis of the project is: the disruption of xCT and uptake of cysteine leads to the reversal 
of resistance to alkylating agents in pancreatic neuroendocrine tumours (PNETs).  
To accomplish the hypothesis we defined 3 aims: 1st  aim will be to address the expression of xCT 
in PNETs cell lines, and the modulation of xCT expression by cysteine and cisplatin; 2nd aim will 
be focused on the effect of xCT inhibition in PNETs cell death, using erastin and sulfasalazine, and 
3rd  aim will be focused on the effect of new nanoformulations in order to disturb cysteine uptake 




Our work allowed to reveal the role of xCT transporter and the role of cysteine in PNETs cell line 
resistance. This cell line showing different response patterns in cysteine transporters activity 
helped to reveal the differences of the transporter in chemoresistance mechanism. It also 
showed that besides xCT transporter other cysteine transporter such as EAAT3 also appeared to 
be involved in the dynamics of chemoresistance mechanism. 
This work was also important to undercover the effect of new nanoformulations in order to 
disturb cysteine uptake by using SeChry and GSH synthesis by using BSO in PNETs cell lines. 
SeChry, but not SeChry@PUREG4-FA, induced cell death in BON-1 cell lines. SeChry cytotoxicity 
can be selective for cancer cells and this was taken in consideration in our new strategy by using 
SeChry@PUREG4-FA, however the assay was not successful and new markers for targeted delivery 
must be investigated in PNETs.  
BSO@PUREG4-FA induced cell death in combination with platinum salts in PNETs cell lines. 
Possibly, the use of folate functionalised particles will help to bypass the critical step in the non-
specific delivery of BSO to non-cancer cell.  The targeted BSO delivery to cancer cells can be 
explored as a novel strategy in cancer therapeutics. 
Moreover, more assays with cancer and non-cancer cells must be done in order to determine if 
folate receptor is in fact a suitable target to delivery drugs to PNETS cells, and find new and more 
specific targets. 
Key-Words: Pancreatic neuroendocrine tumours (PNETs), platinum drugs, GSH, cysteine, xCT,  , 


















                                                                            RESUMO 
 
O cancro é caracterizado como um conjunto de doenças envolvidas no crescimento 
descontrolado das células, com capacidade de invadir ou se espalhar para a outras partes do 
corpo. A carcinogénese é reconhecida como um processo de agregação de alterações genéticas 
e epigenéticas nas células normais levando ao aumento da proliferação e invasão. O tumor 
neuroendócrino pancreático (PNET) é um tumor raro que surge da glândula neuroendócrina e 
ocorre em várias partes do corpo. A taxa de prevalência de PNETs é de cerca de 25 a 30 por 
100.000 habitantes nos Estados Unidos e, de acordo com a Surveillance Epidemiology and End 
Results (SEER), a taxa de incidência de PNETs aumentou cinco vezes entre 1973 e 2011. Os PNETs 
representam aproximadamente 7% de todos os tipos de cancro no pâncreas. Normalmente, a 
taxa de sobrevida dos PNETs em 5 anos é de cerca de 42%. 
Os PNETs são um grupo heterogéneo de distúrbios com sobrevida inferior a 5 anos, devido à falta 
de opções terapêuticas efetivas para doentes com estágios avançados, ausência de 
sintomatologia especialmente no caso de PNETs não funcionais e também ao fenómeno de 
quimiorresistência, dependente de múltiplos mecanismos. Dados recentes mostram que a taxa 
de incidência deste tumor aumenta como resultado de mutações genéticas na linha germinativa. 
No que diz respeito às alterações genéticas, é muito importante explicar as diferenças que 
ocorrem no nível de quimiorresistência. O plano de tratamento dos PNETs varia de acordo com 
o tipo, localização e agressividade do tumor. A cirurgia é o único tratamento em estágio inicial, 
mas em estágios avançados a quimioterapia e a radioterapia são a opção de tratamento mais 
paliativo dos PNETs. A quimioterapia que é principalmente baseada em cisplatina combinada 
com capecitabina tem uma taxa de resposta de tratamento aproximadamente de 30%. A 
cisplatina é responsável pela formação de adutos de DNA, levando a danos no DNA, e induz a 
geração de ROS (espécies reativas de oxigénio), que consequentemente leva ao stresse oxidativo, 
danos celulares e morte. A glutationa (GSH) desempenha um papel importante na manutenção 
do equilíbrio redox intercelular e na desintoxicação. A quimiorresistência pode ser baseada na 
alteração dos mecanismos de desintoxicação e o sistema GSH tem sido apontado como um dos 
mais importantes. A cisteína é um substrato limitante da taxa para a síntese de GSH, e o 
transportador de cisteína xCT  está implicado na gravidade do cancro e na quimiorresistência 
A hipótese do projeto é: a interrupção do xCT e a captação de cisteína levam à reversão da 
resistência aos agentes alquilantes nos tumores neuroendócrinos pancreáticos (PNETs). 
Para testar a hipótese, definimos três objetivos: o primeiro objetivo será abordar a expressão de 
xCT nas linhas celulares de PNETs e a modulação da expressão de xCT por cisteína e cisplatina; O 
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segundo objetivo será focado no efeito da inibição do xCT na morte celular de PNETs, usando 
erastina e sulfassalazina, e o terceiro objetivo será focado no efeito de novas nanoformulações 
para perturbar a captação de cisteína (Sechry e Sechry @ PUREG4-FA) e a síntese de glutationa 
(BSO @ PUREG4-FA).  
 
Este trabalho permitiu revelar o papel do transportador xCT e o papel da cisteína na resistência 
das linhas celulares de PNETs. Estas linhas celulares mostrando diferentes padrões de resposta 
na atividade dos transportadores de cisteína revelaram as diferença no mecanismo de 
quimiorresistência e mostraram que, além do transportador xCT, outro transportador de cisteína, 
como o EAAT3, também poderá estar envolvido na dinâmica do mecanismo de 
quimiorresistência. 
Este trabalho também foi importante para desvendar o efeito de novas nanoformulações, a fim 
de perturbar a captação de cisteína usando a síntese de SeChry e GSH usando BSO nas linhas 
celulares de PNETs. SeChry, mas não SeChry @ PUREG4-FA, induziu a morte celular em linhas 
celulares BON-1. A citotoxicidade de SeChry pode ser seletiva para células cancerígenas e isso foi 
levado em consideração na nossa nova estratégia usando o SeChry @ PUREG4-FA; no entanto, o 
ensaio não foi bem-sucedido e novos marcadores para entrega direcionada devem ser 
investigados nos PNETs. 
BSO @ PUREG4-FA em combinação com sais de platina nas linhas celulares de PNETs induziu 
morte celular. Possivelmente, o uso de partículas funcionalizadas com folato ajudará a contornar 
a etapa crítica na entrega inespecífica de BSO às células não cancerígenas. A entrega direcionada 
de BSO às células cancerígenas pode ser explorada como uma nova estratégia na terapêutica do 
cancro. 
Além disso, mais ensaios com células cancerígenas e não cancerígenas devem ser feitos para 
determinar se o receptor de folato é de facto um alvo adequado para administrar drogas às 
células de PNETs e encontrar novos e mais específicos alvos. 
Palavras-chave: Tumores neuroendócrinos pancreáticos (PNETs), drogas de platina, GSH, 





1.1 Cancer Biology: 
The word cancer came from Greek, karkinos discovered by physician Hippocrates (460–370 B.C) 
to elucidate the carcinogenesis.1 Cancer can be defined as a group of diseases characterised by 
abnormal cell division and alteration of normal cell behaviour leading to limitless growth of cell 
and proliferation.1 In the developed countries, cancer remains the second leading cause of death, 
underlying approximately 10,000,000 deaths around the world.2 
Cancer has some specific biological capabilities, justifying the complexity of neoplastic disease, 
called “Hallmarks” of cancer. The hallmarks of cancer are: sustained proliferative growth signals; 
evasion of antigrowth signalling; resisting programmed cell death; immense replicative capacity; 
induced angiogenesis, and capacity of cancer cell spreading - tissue invasion and metastasis.3  
Reprogramming of energy metabolism and evading immune destruction were added as emerging 
hallmarks of cancer in the last decade .3 
 
In 1956, Otto Warburg established for the first time a connection between alterations in 
metabolism and cancer cells. He stated that a higher aerobic glycolysis was a distinctive feature 
of non-cancer and cancer cells, known as the Warburg effect.4,5,6,7 Other evidence revealed that 
continuous aerobic glycolysis helps the cancer cell to activate oncogenes.6,7,8 Additionally,  the 
cancer cells grow like a mass with low amounts of nutrient and oxygen that prompt the growth 
of new vessels that helps the tumour to proliferate rapidly.9  
 
The cancer cell microenvironment gives signals that lay into the activation of signalling pathways, 
which ultimately activate transcription factors. Besides cancer cells, stromal or non-malignant 
cells, permitting the mesenchymal phenotype that is necessary to invasion and metastasis 
distance; also contribute for a specifically required cancer cells transcriptional program.10 Upon 
metastasis, cancer cells turn off this program and rescue an epithelial phenotype. It is thought 
that tumour microenvironment is playing a crucial role in this process.  
 
1.2 Neuroendocrine tumours:  
In 1969, Pearse identified APUD (amine precursor uptake and decarboxylation) peptide hormone 
secreting cells in the body that share common morphological features for balancing the 
embryological differences.11 APUD cells have autocrine, paracrine and neuromodulator function, 
they are located throughout the body and mostly originated from neural crest.12 
The main function of the neuroendocrine cells is to synthetize hormone in the cytoplasm then 
transport it to axons and from the nerve ending ultimately it is secreted into the vessels.13 
 
Neuroendocrine tumours (NETs), characterized as rare tumours that arise from neuroendocrine 
cells, can occur in various organs of the body, including pancreas, gastrointestinal tract and 
lung.14 The main origin of neuroendocrine cells is not well known. These cells have the behaviour 
of nerve cells and endocrine cells as they secrete hormones into the blood as a response to signals 
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that come from nervous system.15,16  NETs  which stereotypically ascend in the pancreas are 
called islet cell tumours.15,16 NETs can be benign or malignant and they are usually slow growing, 
but sometimes they grow abruptly. 
Symptoms and signs of the NET depend on some factors such as the types of the tumour, the size 
of the tumour, location of the tumour, the pattern in situ or spread and functioning state of the 
tumour such as hormone or non-hormone producing cells.15,16 Detection and progression of  
NETs depend also on the traits of the neuroendocrine cells, because functional NETs may 
overproduce certain hormones inducing a constellation of symptoms related to the hormone 
that is being oversecreted, whereas non-functional NETs are not associated to a specific clinical 
syndrome .17 
Most of the NETs are sporadic whereas some of these tumours are diagnosed in the context of 
to autosomal dominant hereditary cancer syndromes, such as: multiple endocrine neoplasia type 
1 (MEN-1); Von-Hippel–Lindau; tuberous sclerosis and neurofibromatosis type 1.18 
 
Treatment of NETs varies, as it depends on type, stage and aggressiveness of the tumour.19 
Therapeutic approaches, such as surgery and medical therapies may differ between each type of 
NET. 
 
   -  Neuroendocrine tumour cells can be divided into aggregations of cells (glands) and diffusely 




Data from the Surveillance Epidemiology and End Results programme (SEER) including patients 
with NETs from 1937 to 2012 shows that the incidence of neuroendocrine tumours has markedly 
increased over past few years.21 
 




Pancreatic neuroendocrine tumours (PNETs) are a subtype of neuroendocrine tumour derived 
from the islet of Langerhans cells with various morphologies and behaviours, including malignant 
potential.22 
In the United States, the prevalence of PNETs is approximately 25-30 per 100,000 population.30 
It is reported that the incidence rate of PNETs according to the population based report from 
Europe and Asia is near about  <1 per 100 000 persons per year .23,24,25 In addition, their incidence 
in autopsy studies is higher compared to diagnosed cases, ranging from 0.8% to 10%.26  PNETS 
can be functional or non-functional. Functional PNETs are characterised by a hormonal 
hypersecretion syndrome such as hypoglycaemia, hyperglycaemia, glucose intolerance, peptic 
ulceration, watery diarrhoea, hypokalaemia etc. Non- functional PNETs do not produce any 
symptoms, but they cause illness and death by occupying the normal tissue and 
metastasizing.27,28,29 Epidemiology of the PNETs is not well known and there is no difference of 




Biology and Genetics: 
 
In 2000, the World Health Organization (WHO) histologically classified GEP-NENs as: well 
differentiated endocrine carcinoma and poorly differentiated endocrine carcinoma/small cell 
carcinoma. However, in 2010 they categorized the Classification based on Ki-67 proliferation 
index and mitotic count, as: neuroendocrine tumour grade 1 (NET-G1); neuroendocrine tumour 
grade 2 (NET-G2), and neuroendocrine carcinoma.31 Mitotic count ranges from <2 to >29 per HPF 
(high power field) and Ki-67 proliferation index <3% to >20% per HPF according to the grade of 
tumour.31 
Genetic information provides a better knowledge for the development of new treatment agent 
in the field of research. Genetic differentiation between the different grades of tumour in PNETs 
also gives us useful information to better understand the biology of PNETs. In 2009 Capelli et al. 
reported MEN1 gene mutation as the most common hereditary irregularity in the germline PNETs 
causing biallelic inactivation due to the fact that a mutation in one allele induces the loss of the 
second allele. MEN1 gene is a tumour suppressor gene and its germline mutation influences the 
development of multiple endocrine neoplasia syndrome type 1.32 Mutations in ATRX (α-
thalassemia/mental retardation syndrome x-linked) and DAXX (Death -domain associated 
protein) genes are reported as the most common somatic events involved in PNETs. Both genes 
are associated with chromatin remodelling in the telomeres and the encoded proteins of the 
genes are networked with one another.33 In addition, based on the molecular pathway of poorly 
differentiated PNETs, cancer cells can be derived from the normal neuroendocrine cells which 
acquired mutations of TP53 and SMAD4 concomitant with KRAS mutations.34  
 
Therapy: 
The therapeutic approach for the PNETs patients differs, depending on the type, location, stages 
and aggressiveness of the tumour. Generally, it is divided into three levels, such as surgery, anti-
proliferative and symptomatic therapies.34   
Imaging studies are used to evaluate the extent and the location of the tumour, so that proper 
management can be taken.35 From past to present day, surgery with regional lymph node 
resection is the only curative treatment recommended for the early stage PNETs and is specially 
used to prevent complications in PNET patients.36 However, in advanced stages, surgery is usually 
not feasible and systemic therapy becomes the main treatment option. However, in patients with 
advanced PNETs and liver metastasis, partial hepatectomy may be recommended, depending on 
the patient response, size and location of primary tumour.36 Chemotherapy and radiotherapy are 





1.3 Chemotherapeutic agents:  
Platinum based chemotherapy is the most frequently used chemotherapeutic strategy. Platinum 
drugs such as cisplatin, carboplatin or oxaliplatin are commonly combined with taxanes 
(paclitaxel or docetaxel). Cisplatin is a first line chemotherapeutic agent with the highest side 
effects. Carboplatin is the second-generation antineoplastic agent containing platinum. The main 
differences between carboplatin and cisplatin are that carboplatin has a 
cyclobutanedicarboxylate group, being more stable but to achieve the same effect as cisplatin 
this drug need to be applied in a higher concentration. Within this group of drugs, carboplatin is 
the best option as a neoadjuvant, adjuvant and palliative treatment because of its less side 
effects.38,39   
Chemotherapy is the treatment for the advanced stage with unresectable pancreas tumour, 
resulting in an increase in overall survival of patients.40 When a patient shows symptomatic 
features and/or has a tumour with a ki-67 value more than 10%, cytotoxic chemotherapy is well-
thought-out as a first line of treatment. Two different groups of medications are utilized for the 
treatment purpose of well differentiated PNETs. They are alkylating agents such as platinum salts, 
Streptozocin (STZ), temozolomide (TEM), dacarbazine (DTIC) and antimetabolite agents such as 
5-flurouracil (5FU), capecitabine (CAP) and doxorubicin (DOX). Nowadays, combination of STZ 
and 5FU is prescribed commonly instead of STZ and DOX combination.  The limitation of use of 
DOX is due to cardiotoxicity with a dose of 50 mg/m2, as reported.41 STZ is a diabetogenic 
substance, which is selectively incorporated into the beta cells of the pancreas via GLUT2 
transporters that leads to cytotoxicity and the generation of reactive oxygen species (ROS). On 
the other hand, another combination of drugs, TEM combined with CAP, is recommended as an 
alternative treatment in well differentiated PNETs patients. In advanced cases of neuroendocrine 
tumours / neuroendocrine carcinomas, cisplatin-based chemotherapy is standard (generally, 
cisplatin and etoposide).41 
 
1.4 Chemoresistance:  
Chemoresistance is one of the most challenging issues in the field of cancer treatment. 
Consequently, to find out novel therapeutic approaches it is vital to know the molecular 
mechanisms of the chemoresistance, because it causes recurrence, relapse and death.42 
Chemoresistance can be divided into two categories, one is intrinsic (de novo or innate) and 
another is acquired resistance.43 
Intrinsic resistance is characterized as a circumstance when chemotherapy is not enough from 
the beginning of the treatment because of the patient endogenous component, on the other 
hand,  when the tumour grows slowly after exposure of anticancer medications, because of 
epigenetic or molecular adjustment of malignant cells, it is known as acquired resistance.44 There 
are many diverse mechanisms involved in chemoresistance such as alterations of drug transport 
pump, modification of drug target interaction, enhanced DNA repair activity, augmented drug 
damage tolerance, effect on protein associated with detoxification process and imperfection in 
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apoptotic pathway.45 In advanced stages of pancreatic cancer,  chemotherapy is the most 
effective treatment. Nevertheless, many patients lean towards the relapse of disease and 
chemoresistance.46 
To understand the chemoresistance mechanism related to transport pumps, it is important to 
focus on p-glycoprotein. P-glycoproteins are membrane proteins, including Multidrug resistance 
protein 1 (MDR1) or ATP binding Cassette (ABC) protein, acting as an ATP -dependent efflux 
pump. These proteins cause decreased drug intracellular accumulation by altering the 
intracellular pH.38 There are some other transporters such as Breast Cancer Resistance Protein 
(BCRP) and Major Vault Protein (MVP). BCRP bearing circulating microvesicles contribute to the 
mechanism of chemoresistance in breast cancer.47 MVP possibly will facilitate chemoresistance 
by controlling the nucleo-cytoplasmic transport (hormones, ribosomal RNAs, drugs).38 
Modification of drug target expression or mutation causes alterations in drug targeting that 
ultimately leads to drug resistance in cancer. For example, a mutation in the topoisomerase II 
gene leads to reduced efficacy of topoisomerase inhibitors, affecting DNA synthesis, DNA damage 
and halting of mitotic processes. Some anticancer drugs target signalling kinases such as 
epidermal growth factor receptor (EGFR), Ras, Src, Raf, and MEK. In addition, some of these 
kinases are constantly active in certain types of cancer, leading to uncontrolled cell growth.48  
In the field of cancer drug resistance, enhanced DNA repair and tolerance of damaged DNA are 
thought to be one of the possible mechanisms of chemoresistance. The role of chemotherapeutic 
agents is to damage the DNA of cancer cells indirectly or directly and DNA repair mechanisms fix 
the damage of the DNA49. It is known that platinum based chemotherapeutic agents cause 
apoptosis of cancer cell through damaging the DNA.50 
It is thought that polymerase enzymes play an important role in the process of drug tolerance. 
The normal DNA replication process requires the action of error free DNA polymerase. Moreover, 
when DNA injury cannot be repaired, in order to sustain the cell survival, the injury should be 
tolerated, and this can be accomplished by translational synthesis pathway catalysed by DNA 
Polymerase.51 
Drug damage tolerance is associated with reduced susceptibility to apoptosis. Catalytic caspases, 
which are associated to a group of cysteine-dependent aspartate-directed proteases, have their 
activity dependent on the formation of tetrahedral intermediates via promoting a cysteine 
residue that is linked with apoptotic activity and signalling. In addition, genes that regulate 
apoptosis are altered in this mechanism, accounting for apoptosis inhibition.52,53 
Effect on proteins associated with the detoxification process, as glutathione and its related 
enzymes, is another chemoresistance mechanism. Glutathione plays an important role in the 
process of detoxification. Glutathione-s-transferase (GST) superfamily network is an important 
example of drug activation and inactivation process.  GST contributes for the progress of drug 
resistance mechanism by direct detoxification and through inhibiting the pathway of mitogen 
activated protein kinase (MAPK).48   The higher GSH level with over expression of glutathione-s-
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transferase (GST) will increase the proportion of conjugation and detoxification reduces the 
effectiveness of therapeutic agents.54 Cytochrome P450 (CYP) is also involved in the process of 
drug activation and inactivation. CYP is divided into two classes: Class I includes CYP1A1, CYP1A2, 
CYP2E1, CYP3A4 and Class II includes CYP2B6, CYP2C9, CYP2C19, CYP2D6. Class II has a 
characteristic feature of high polymorphism rate that is involved in the metabolism of cancer 
drugs and in drug resistance mechanism.48 Uridine diphosphate- glucuronosyltransferase (UGT) 
superfamily, which is a group of transferase enzymes involved in glucuronidation catalysis,  
regulating the formation of inactive hydrophilic glucuronides with substrates together with 
environmental carcinogens and cytotoxic. The expression of UDP glycosyltransferase family -1, 
member 1 (UGT1A1) thought to be negatively regulated by DNA methylation meanwhile due to 
epigenetic changes the overexpression of UGT1A1 is common in cancerous state, that ultimately 
leads to drug detoxification.41 
Programmed cell death is markedly influenced by a variety of genes, some of them are mutated 
or difunctionally regulated. Defective cell death can occur as a result of aberrant regulation of 
TP53 and PTEN, inhibitors of the PI3K/AKT pathway, which might impair the affiliation between 
DNA damage and the activation of programmed cell death, increasing chemoresistance and 
leading to drug induced apoptosis failure.54  TP53 inhibits PI3K ultimately abolishing the 
mitochondrial p53 -dependent apoptosis. PTEN is an inhibitor of PI3K for the synthesis of PIP3 by 
phosphorylation, which will activate AKT. When PTEN in downregulated or inhibited, PI3K will be 
activated, PIP3 will be synthesized and AKT activated.55,56 Apoptosis is activated by the cleavage 
of executioner caspases (eg. 3 or 7). There are two routes to apoptosis: extrinsic (or death 
receptors) and intrinsic or (mitochondrial).57,58 Extrinsic pathway is regulated by the action of FAS 
and TNF- on the death receptors and it is mainly dependent on caspase 8 activation that will 
cleave the executioner caspases. Within the external pathway mutations, epigenetic or post-
translational alterations may affect proteins function, which ultimately lead to the inhibition of 
cell death in cancer cells.57,58,59 Within the intrinsic pathway the up regulation of the anti-
apoptotic genes (eg. Bcl2) and down regulation of pro apoptotic genes (eg. Bax, Bclxl) in tumour 
cells lead to resistance to chemotherapeutic agents.60 XIAP is also an inhibitor of caspases 3, 7 
and 9, affecting both apoptosis pathways.57TP53 is the master regulator of apoptosis, being an 
activator of both intrinsic and extrinsic pathways, in cancer deregulation and mutation of TP53 
affects apoptosis through the inhibition of mitochondrial and death receptor signalling. 57,61 
 
1.5 Cancer metabolism.   
The basic principle of cancer metabolism is that metabolic activities are changed in the cancer 
cells compared to normal cells. In 2011, Weinberg et. al. added a new hallmark of cancer that is 
reprogramming of cancer metabolism. The metabolic reprogramming has a reflective effect on 
gene expression, cellular proliferation and tumour microenvironment.54   Otto Warburg in 1923, 
first made the connection between cancer and metabolism in the basis of the concept of Warburg 
effect, assuming that cancer cells would preferentially fulfil glycolysis instead of oxidative 
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phosphorylation (OXPHOS).62  Metabolism not only is related to intracellular network, but is also 
related with extracellular organic and communication molecules, which control the complete 
metabolic function of the cell.  Fibroblasts are the most important  type of tumour stromal cells,  
playing a vital role in the process of cancer cell progression through their molecular 
cooperation.63  CAFs (cancer associated fibroblasts) and neoplasm cells permit an enhanced 
microenvironment, vital for neoplasm survival, proliferation, migration and chemoresistance.64,65  
CAFs  are crucial in the metabolic process to organize the inner source of nutrients providing the 
Krebs cycle with metabolic intermediates.66 Fatty acids are major contributors for tricarboxylic 
acid (TCA) cycle, that is required for the generation of nicotinamide adenine dinucleotide (NADH), 
vital for OXPHOS.63 Reactive oxygen species (ROS) are short lived molecules with unpaired 
electrons that are constantly generated, modified and eliminated during the cellular processes 
together with metabolism, proliferation, differentiation, processes of immune system regulation 
and remodelling of vascular system; but the excess amount of ROS causes oxidative stress and 
altered cancer metabolism.67  Excess production of ROS causes alterations of sulfhydryl groups 
of private kinase M2 (PKM2) leading to shunting of glucose away from glycolysis towards the 
pentose phosphate pathway (PPP), which produces NADPH and nucleotides, favouring cell 
proliferation.72 The NADPH reduces glutathione into an active antioxidant, functioning as a cell 
protector and maintain the redox homeostasis.68,69 
 
1.5.1 GSH and Cysteine: 
Glutathione (GSH) and cysteine are both thiols, having a sulfhydryl or thiol group, made of 
sulphur and hydrogen atoms attached to a carbon. GSH is a low molecular weight thiol composed 
of glutamic acid, cysteine and glycine. GSH is very reactive and can conjugate with another 
molecule via sulfhydryl group. The bulk of GSH found intracellularly within the cytoplasm is 
approximately 90%, about 10% is found in mitochondria and a little amount is found in the 
endoplasmic reticulum.70 GSH is synthesized by two ATP requiring enzymes glutamate cysteine 
ligase (GCL) and GSH synthetase (GSS). The synthesis of GSH is catalysed by GCL which have two 
subunits, one is GCLC (glutamate cysteine ligase catalytic subunit) that catalyses the linkage 
between the amine group of cysteine and the γ-carboxyl group of glutamic acid; and another is 
GCLM (glutamate cysteine ligase modifier) that increases the catalytic activity by interacting with 
GCLC. GSH synthetase catalyses the reduction of gamma-glutamylcystein and glycine to create 
GSH.71 Then this gamma-glutamylcystein can be transported back into the cells and again 
metabolized into 5-oxoproline, ultimately converted to glutamate and used in GSH synthesis.   
The rate of GSH synthesis largely depends on cysteine availability and the activity of GCL. Cysteine 
plays a key role in the maintenance of protein structure and synthesis. The proper concentration 
of intracellular cysteine also helps to maintain the redox homeostasis.72 
GSH is the most reduced form, which is being oxidized in the form of GSSG via its direct reaction 
with ROS or substitute as a co-enzyme for antioxidant like glutathione peroxidase (GPX) and 
recycled by glutathione reductase (GR).73,74,75 GPX is the member of the family of selenium -
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dependent enzymes, which can differ from transferases because of its activation with hydrogen 
peroxide (H2O2). GPX enzymes use glutathione like a ROS scavenger, that convert H2O2 to water 
and lipid peroxides.75,76 Glutathione plays an important role in the maintenance of redox balance 
and protein status. The glutathione   reaction with the protein varies with the concentration of 
GSH and GSSG. But the reversible thiolation reaction of proteins is responsible for the regulation 
of numerous metabolic processes such as enzymatic activity, signal transduction and gene 
expression with the help of redox sensitive nuclear transcription factor   like AP-1, NF- kappa B 
and TP53.77,78 
Another important function of GSH is the storage of cysteine because it is unstable extracellularly 
and rapidly oxidized to cystine through a process that produces toxic ROS. The -glutamyl cycle 
helps GSH in this procedure of releasing cysteine. In this cycle, GGT transfers the -glutamyl to an 
amino acid to form γ-glutamyl-aa and cysteinyl-glycine. GSH  plays an important role not only in 
the protection of cells against apoptosis but it also has an extreme key role  in detoxification 
process, and its disruption will activate diverse transcription factors like activator protein -1 (AP-
1), activator protein -2 (AP-2), stress activated protein kinase (SAPK) and  c-Jun-N -terminal kinase 
(JNK). Besides, GSH acts as an antioxidant .71,79, it is also involved in DNA repair and synthesis and 
prostaglandin synthesis.80 Increased levels of GSH are considered as a causative factor of drug 
resistance through binding to or interacting with the drug or ROS, preventing harm to protein or 
DNA or by taking part in the DNA repair process.68 However,  specific GSTs overexpression can 
even influence chemoresistance, while polymorphisms which  reduce GST activity are related to 
a high risk of developing cancer.73 In combination,  it will also increase the percentage of 
conjugation and detoxification of chemotherapeutic agents,   that ultimately reduces their 
effectiveness .81 Higher expression of GST can switch the balance of kinases that will cause a 
potential benefit for cancer development.73 
 
1.5.1.1 Cysteine metabolism 
Cysteine is a semi essential amino acid which is mainly provided through diet or through the 
trans-sulphuration pathway. Serine and methionine-derived homocysteine reaction are 
catalysed through cystathionine-β-synthase (CBS) to form cystathionine, then the pathway is 
facilitated by cystathionine--lyase (CSE) and catalyses its final step through the conversion of L-
cystathionine to cysteine and α-ketobutyrate. 82 
Cysteine degradation is also a crucial metabolic reaction. Multienzymes are involved in this 
procedure. The process of sulfane sulphur generation from cysteine, homocysteine and their 
disulphides is carried out through three enzymes that are CBS, CSE and 3-mercapto-pyruvate 
sulphur transferase (MpST) along with cysteine aminotransferase (CAT). CSE is responsible for 
catalysing the conversion of L-cystine to thiocysteine, pyruvate, and ammonia. After that, 
thiocysteine in the presence of thiol forms cysteine and inorganic sulphur from hydrogen 
sulphide (H2S) and cystine.83 MpST enzyme is responsible for the relocation of sulphur ion from 
3-mercaptopyruvate toward a thiolic compound.84  MpST and CAT enzymes are in mitochondria 
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and are responsible for mitochondrial ATP production dependent on H2S, while CBS and CSE are 
repositioned in mitochondria under cellular stress.85   L-cysteine is also degraded by the help of 
cysteine dioxygenase (CDO). Cysteine dioxygenase is accountable for adding an oxygen molecule 
to sulphur of cysteine, which is converted  to sulfinic acid, known as cysteine-sulfinic acid. After 
that, cysteine-sulfinic acid is again metabolised into either one pyruvate and sulfate or to taurine 
and CO2.86   
It has been reported through literature that cysteine is a tumorigenic promoter. Pancreatic 
cancer cells need an exogenous source of cysteine because of its crucial role in redox homeostasis 
contributing for tumour growth and maintenance. Cancer cells depend on oxidized cysteine, 
which detoxifies the lipid ROS and prevents ferroptosis. 87 
 
1.5.1.2 Cyst(e)ine /Glutamate transporter: Cysteine transportation is mediated by alanine -
serine-cysteine transport system (ASCT), excitatory amino acid transporters (EAATs) system and 
the Xc- (xCT) system. ASCT system includes ASCT1 and 2, in which Na+ dependent mediated 
transport exchanges small neutral amino acids like alanine, serine, threonine and cysteine and 
structure of the transport. EAATs mediate the transport of amino acids along with the co -
transport of K+ via producing a net flux of charges. xC- system depends on xCT transporter, a 
glutamate and cystine (the oxidized form of cysteine) antiporter that relies on proton 
electrochemical gradient.88,89 
 
 1.5.1.2.1 System xC-(xCT): System xC- was first explained by Bannai and Kitamura in 1980 in 
culture of human fetal lung fibroblasts, which work as a sodium independent and chloride 
dependent antiporter system, being capable of transporting an anionic form of cysteine and 
glutamate in both directions.90,91,92  Cystine is the oxidised form of cysteine, which is rapidly   
reduced and therefore the intracellular glutamate concentration is mostly elevated comparing 
with the extracellular space, this mechanism basically relies on the concomitant cysteine import 
and glutamate export.93 
The xCT transporter is encoded by solute carrier family 7-member 11 (SLC7A11) gene, located on 
chromosome 4 (4q28.3). xCT/SLC7A11 gene has an antioxidant responsive element region (ARE) 
in its promoter that is controlled by the regulation of nuclear factor erythroid 2-related factor 2 
(NRF2), which plays an important role in cellular protection against oxidative stress. In 2018, 
Carpi-Santos et al. found that alterations in xCT expression affected the retina of diabetic rats via 
regulation of NRF2.94,95  Meizi et.al made an experiment with the aim of making a link between 
sepsis illness and protein interaction with C-kinase 1 (PICK1). Through this experiment they found 
that deficiency of PICK1 not only causes the inhibition of xCT expression, but also reduces the 
GSH synthesis, which ultimately leads to severe oxidative stress.96    xCT activity also has a role in 
cancer. In invasive breast cancer and oesophageal squamous cell carcinomas, expression of xCT 
is negatively correlated with survival.97   Besides overall function, it is also reported that system 
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xCT also plays an important role in the immune system. xCT overall acts as an anti-oxidant, it 
contributes for cysteine uptake and GSH synthesis, ultimately solving the oxidative stress.88,98 
xCT transporter is made of a light chain (xCT) and a heavy chain (4F2hc) and both chains are 
connected through a disulphide bridge. However, the heavy chain is responsible to link with 
specific amino acids of the light chain to form a heterodimer.74,88,99  In the cell membrane, xCT is 
necessary to uptake the enough cysteine that is required for the GSH synthesis, which acts as an 
antioxidant for the maintenance of intracellular redox balance.93,100 xCT is not only highly 
expressed in a variety of cancer cells like breast cancer, prostate cancer, lymphoma and glioma, 
but it is also engaged in various cellular functions in cancer cells like chemoresistance. 
101,102,103,104,105,106 It is known that neurotransmitter glutamate depends on xCT, so the role of xCT 
is well known in brain or central nervous system (CNS).   It has been found that CNS dysfunction, 
accompanied by neural oxidative stress and accumulation of glutamate in the extracellular space, 
causes the reduction of cysteine import in the cell and increases the production of ROS which 
ultimately leads to excitotoxicity.87 It is also observed that glioblastoma cells show higher 
expression of xCT.88,107 
xCT transport system has a role in cancer context since it causes increased levels of GSH, involved 
in the process of chemoresistance.108,109 But the inhibition of xCT function also interferes with its 
expression. Sulfasalazine and Erastin are well known inhibitors of this transport system.108,110 
Sulfasalazine is a drug which is used in inflammatory bowel disease and rheumatoid arthritis. 
Approximately 90% of sulfasalazine reaches the colon and it is metabolized into sulfapyridine and 
mesalazine by the help of bacteria.111 Recently, it has been appointed as an inhibitor of  xCT, but 
the mechanism of action remains unclear.88 A recent study found that sulfasalazine along with 
autophagy-inducing agent temozolomide produce higher efficacy of chemotherapy drug in 
glioma treatment.112  It is known that caveolin-1 pathway is involved in the process of tumour 
metastasis. Some recent experimental data provided evidence that sulfasalazine by interfering 
with the pathway of caveolin-1 causes the reduction of GSH levels, which ultimately reduces 
tumour metastasis in oesophageal squamous cell carcinoma.113 Data collected from current 
studies demonstrate that xCT has a major role in pancreatic cancer via enhancing the GSH 
synthesis, whereas sulfasalazine known as a nontoxic drug combined with gemcitabine initiates 
an effective treatment in pancreatic cancer. 114 
Erastin is a small molecule binding with voltage-dependent anion channels (VDAC) which are 
responsible for the initiation of iron dependent cell death known as ferroptosis. Erastin acts as 
an inducer of ferroptosis by reducing cysteine uptake and diminishing the synthesis of GSH, 
ultimately maintaining the redox homeostasis.115 It was proven by some studies that RNA 
interference mediated knockdown of VDAC2 or VDAC3 causes resistance to Erastin.116 VDAC2 or 
VDAC3, which are the two isoforms of VDAC are involved in inhibiting the cysteine/glutamate 
transporter system. In addition, Erastin can inhibit the activity of GPX-4, which is a GSH related 
enzyme giving rise to oxidative damage to cells.117 It has a robust inhibitory effect on xCT activity 
compared to sulfasalazine. 118 In 2007, Yagoda. et al. recognized that Erastin showed evidence in 
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tumour cell death with harbouring mutations in RAS-RAF-MEK genes. They also found that this 
drug changed the permeability of the outer mitochondrial membrane, indicating that maybe 
Erastin induces apoptosis in cancer cells.116   
 
1.6 New strategies to disturb xCT and cysteine /GSH metabolism by using selenium-chrysin 
(SeChry) and buthionine sulfoximine (BSO) 
Selenium (Se), acts as a cofactor of mammalian enzymes, such as glutathione peroxidase, 
functioning as a great antioxidant.119 It is known that cancer cells are more sensitive to Se induced 
cytotoxicity than non-cancer cells.120,121 Se produces ROS and instigates DNA strand breaks with 
subsequent cell cycle arrest and apoptosis, leading to tumour growth suppression.122,123 Pro-
oxidative effects of inorganic Se compounds were attributed to the antitumor mechanism, 
instead of antioxidative effects of organic selenium compound.124 Se is  incorporated into 
selenoproteins and the link between selenoproteins and cancer depends on the anti-oxidant 
properties of selenoproteins including the enzymes of glutathione peroxidase (Gpx) family, 
responsible for antioxidant protection against ROS.125 High ROS generation induces continuous 
oxidative stress that provides expression of malignant phenotype of cancer cells.126 Se metabolite 
conjugates to two glutathione (GSH) moieties, known as selenodiglutathione (SDG), increasing 
intracellular accumulation of Se. Evidences suggest that SDG in Se incorporation proceeds at cell 
surface by gamma-glutamyl transpeptidase (GGT), prompting the creation of selenocysteine, 
which is probably going to be exported through xCT. This mechanism could be arbitrated by xCT 
and may cause the Se induced cancer specific toxicity.119 As it is known, xCT transporter is related 
to cancer drug resistance, in an effort to reduce the detoxifying activity through increasing the 
uptake of cysteine, accounting for GSh synthesis. Hence, selenated-compounds were taking in 
thought as potential xCT inhibitors.127,87 Selenium-chrysin (SeChry) is an organoselenium  
compound composed of a selenium group and chrysin, a flavone, having anti-tumoral and anti-
oxidant properties,  by protecting cells from toxic compounds and on the other hand, by inducing 
apoptosis.128,129,130 
Buthionine sulfoximine (BSO) is a specific γ-glutamylcysteine inhibitor, developed by Griffith and 
Meister that reduced cellular GSH levels biosynthesis. BSO is a chiral compound and consists of 
two isomers, one is L-buthionine-(R)-sulfoximine and the other one is L-buthionine-(S)-
sulfoximine. 131 L-buthionine-(S)-sulfoximine has a greater role in the inhibition of γ-GCS in 
relation to is  L-buthionine-(R)-sulfoximine in cell culture and in animals.132,133 It was  utilized in 
numerous investigations to reveal a decrease in GSH, sensitizing both cell lines and 
animals.134,135,136 As above-mentioned, GSH is the most commonly found intracellular thiol, its 
depletion by BSO prompts oxidative stress, ultimately leading to increased radiation 
sensitivity.137 In addition, BSO sensitizes cancer cells to chemotherapy.138,139 Preliminary studies 
from our group and studies from other teams revealed that continuous infusion of BSO  give rise 
to the depletion of tumour GSH in patients with advanced cancers, specially ovarian cancer,140,141 
which prompt us to test this compound in PNETs . 
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Cancer cells express higher levels of folate receptor than normal cells 142,143 and folate receptor 
targeted therapy is a way of directing nanoparticles to cancer cells both in vitro and in vivo.143,144 
So, in an attempt to improve the specificity of SeChry and BSO towards cancer cells, folate 
receptor targeted delivery of these compounds was performed using SeChry@PUREG4-FA 
nanoparticles as a drug delivery system.145,146,147 
 
1.7 Metabolic profiles of PNET  
Metabolic alterations in neoplastic cells is nowadays considered as a hallmark of cancer.3 In 
addition, metabolic reprogramming accelerates the proliferation of cancer cells.148 Most of the 
cancer cells depend on the amino acid glutamine, instead of glucose, to fulfil their biosynthesis 
need.149 As it was previously explained that PNET can exhibit mutations of TP53 with activating 
KRAS mutations, it is thought that KRAS driven metabolic alterations might have a prominent role 
in PNET proliferation. In pancreatic ductal adenocarcinoma, mutated tumour suppressor genes 
such as TP53, SMAD4 have a significant role in the process of carcinogenesis.150 It is proven that 
elevated glycolysis flux causes a boost up the downstream pathway of KRAS. In the context of 
cancer, mutated KRAS transcriptionally upregulates the GLUT1 that ultimately causes elevated 
glucose uptake.151,152In glycolysis, pyruvate is converted to lactate upon the action of lactate 
dehydrogenase enzyme (LDH). Mutated KRAS also has a role in increasing LDHA expression.116 
 
 1.7.1 Thiols (including GSH and Cysteine) metabolism in PNET: Thiols especially GSH interfere 
with complex tumorigenic process. GSH conjugation of electrophilic carcinogens may prevent 
tumour initiation and defend cells against oxidative stress. It is thought that enhancement of 
antioxidants or conjugating capacity by increasing the levels of GSH, via precursor application, 
synthesis stimulation or inducing the related enzymes, may constitute a chemo preventive cell 
strategy.153 
GPX-1 (GPX-1), which is a member of GPX family, is known as an enzyme that is related to tumour 
initiation and progression via modulating intracellular ROS by eliminating 
hydroperoxides.154,155,156 Interestingly, the relation between this enzyme and pancreatic cancer 
is not well known, even though it was already proven by some experimental work that GPX-1 
expression is directly linked to the initiation and progression of several malignancies such as 
breast, bladder and prostate cancer.157,158,159  It is thought that GPX-1 might have some role in 
pancreatic cancer, although showing some controversy, as it seems that the abrogation of GPX-
1 is related to pro-metastatic pathways dependent on ROS.160 However, in PNET there are no 
studies on the role of thiols and related enzymes in disease progression. ROS have double roles, 
as hydroperoxides they promote tumour proliferation, migration and the process of 
angiogenesis, whereas excessive production causes cell apoptosis.161 
Dietary source is considered as an etiological factor for pancreatic cancer. Therefore, some 
studies already proved that deficiency of dietary sources of methyl group like choline, 
methionine, vitamin B-12 and folate have a direct role in pancreatic dysfunction, in addition these 
elements have a role in developing various types of cancer including pancreatic cancer. 162,163,164 
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Folate has a methyl group, which is required for the intracellular methylation reaction. In folate 
metabolism methylene tetrahydrofolate reductase (MTHFR) catalyses the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the principle form of folate in 
the blood and acts as a co-substrate to form methionine from homocysteine. 165 Low levels of 
folate are associated with the incorporation of uracil instead of thymine into DNA, which 
ultimately elevate the risk of DNA mutations and DNA strand breakage.166 Data collected from a 
case control study conducted by Shirisha et. al showed the that percentage of direct DNA damage 
was higher in pancreatic cancer patients comparing to healthy individuals. 167 In addition, folate 
pathway has an important role in the process of DNA synthesis and repair.166 It is thought that 
altered folate metabolic pathway, might have some role in pancreatic cancer, as well as in PNET.  
Nevertheless, as far as we know, the knowledge about metabolic alterations in PNET, 

































2. Hypothesis and Aims: 
The Hypothesis of the project is: the disruption of xCT and uptake of cysteine leads to the reversal 
of resistance to alkylating agents in pancreatic neuroendocrine tumours (PNETs).  
This thesis project has three main objectives: 
First aim will be to address the expression of xCT in PNETs cell lines, and the modulation of xCT 
expression by cysteine and cisplatin. 
 
Second aim will be focused on the effect of xCT inhibition in PNETs cell death, using erastin and 
sulfasalazine. 
 
Third aim will be focused on the effect of new nanoformulations in order to disturb cysteine 




















3. Experimental procedures  
 
3.1 Cell Culture 
Two different pancreatic neuroendocrine tumours (PNETs) cell lines were used: BON-1 
(CVCL_3985; JCRB cell Bank) and QGP-1 (CVCL_3143; JCRB cell Bank).  BON-1 cell line was 
cultured in Dulbecco’s Modified Essential Medium/Nutrient mixture F- 12 (Ham) 1x (DMEM F-12) 
(11330-032, Gibco, Life Technologies)  and QGP -1  cell line was cultured in Roswell Park Memorial 
Institute  (RPMI ) 1640 Medium 1x  (12-167F, Lonza, Bioscience), L-glutamine supplemented. Both 
mediums were supplemented with Fetal Bovine Serum 10% (FBS) (S 0615, Merck), Antibiotic-
Antimycotic (AA) 1% (P06-07300, PAN Biotech) and Gentamicin 1% (15750-060, Gibco, Life 
Technologies). Cells were preserved under a temperature of 370C, 5% CO2 in a humified 
environment. The cells were cultured until 75% -100% optimal confluence before they were 
detached with 0.05% Trypsin- Ethylenediamine Tetra-acetic Acid (EDTA) (25300-054, Invitrogen, 
Thermo Fisher Scientific) at room temperature for 5min. Cell number was determined using a 
Bürker counting chamber.   
For cell viability analysis, 2 x 105 cells/mL were plated in 24 well-plates (500 µL/well) and for 
western blotting 2.5 x 105 cells/mL were plated in 6 well-plates (2 mL/well). 
After 8 h of starvation (FBS free culture medium), cells were exposed to L-cysteine (0.402 mM); 
cisplatin (0.025 mg/mL), sulfasalazine (0.25 mM) and erastin (5 µM) isolated or in combination, 
in 1% FBS culture medium for 16 h. 
In BON-1 data, a homozygous (AF 100%) g.114713908TOC mutation (ENSP00000358548 p.Q61R) 
was found in codon 61 in NRAS. Furthermore, a heterozygous g.25245350COA mutation 
(ENSP00000 308495 p.G12V) with an allelic ratio of 0.71 was originate in the KRAS gene in QGP 
1. Data collected from (Whole -exome characterization of pancreatic neuroendocrine tumour cell 
lines BON- 1 and QGP -1). 
 
3.2 Flow Cytometry -cell death analysis 
To evaluate the effect of cysteine (0.402 mM), cisplatin (0.025 mg/mL), erastin (5 µM), 
sulfasalazine (0.25 mM) and BSO@PUREG4-FA (456 µM) under (8h) starvation with 16h of 
experimental conditions  and in SeChry@PUREG4-FA (19 µM) without starvation with 24 h of 
experimental conditions  in PNET cell lines, cell death analysis by flow cytometry was performed. 
Flow Cytometry is a most commonly used technical method to measure the physical and chemical 
characteristics of cells. The most common typical feature of apoptotic cells is characterized by 
fragmentation and loss of nuclear DNA. Upon apoptosis the plasma membrane undergoes some 
structural changes and phosphatidyl serine (PS) is translocated onto the cell surface. Moreover, 
when the apoptotic process is started PS is translocated in the outer leaflet of the plasma 
membrane surface. Annexin V helps to identify the apoptotic cells by binding to PS. Red 
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fluorescent propidium iodide (PI) is also used to stain the necrotic cells. When the cell membrane 
is disrupted, it binds to double strand DNA by intercalating between base pairs, thus allowing PI 
entering into the cell and staining necrotic cells.168,169,170 
Furthermore, cells were collected. Supernatant from each well was collected to an Eppendorf 
and adherent cells were harvested with 100 µL of 0.05 % trypsin -EDTA (25300-054, Invitrogen), 
after that cells were collected to the same Eppendorf, in which the supernatant was at first 
collected. This way, it was ensured that all the cells that were in suspension in culture medium 
and adherent were analysed. Cells were centrifuged at 255 × g at room temperature for 2 min. 
The supernatant was discarded and cells were washed with PBS 1X - 0.1% BSA and stained with 
0.5 µL FITC- Annexin V (640906, Bio Legend) (100 µg/mL) in 100 µL annexin V binding buffer 1X 
for each sample and then incubated in a dark place at room temperature for 15 mins. After that 
samples were rinsed with 100 µL PBS (1X) -0.1% of BSA, and centrifuged at 255 × g for 2 min. 
Cells were resuspended in 200 µL of annexin V binding buffer 1X 10 mM Hepes (pH 7.4), 0.14 M 
sodium chloride (NaCl), 2.5 mM calcium chloride (CaCl2). 2.5 µL of propidium iodide (PI; 50 µL/mL) 
were added to all the samples, 5 min prior the acquisition in a FACS calibur (Becton Dickinson). 
Flow cytometry data was analysed by Flow Jo software. 
 
3.3 Western Blotting 
Western blotting is a widely used technique in cellular and molecular biology to identify the 
specific proteins from a complex mixture extracted from cells. In western blotting, through a 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) a mixture of proteins is 
separated, according to the molecular weight. After the electrophoresis, proteins are transferred, 
under an electric field, onto a nitrocellulose or polyvinylidene fluoride (PVDF) membrane and 
further incubated with an antibody specific for the protein we intend to identify. After the 
recognition of this antibody with a secondary antibody peroxidase conjugated and the chemo-
luminescent development with the peroxidase substrate, luminol; a band for the protein of 
interest will be revealed.171 
For western blotting the cells were cultured in 6 well-plate, afterwards cells were collected by 
scraping or by incubation of PBS (1X) + 2% EDTA. Then cells were centrifuged at 255 × g, cell 
extracts were performed by lysing cells with Radio-Immunoprecipitation Assay (RIPA) buffer and 
stored at -200C.  
Cell lysates were centrifuged (Eppendorf) at 10600 × g for 5 min at 40C and supernatant were 
collected. Protein concentration was measured through the Bradford method, using Bio-Rad 
protein assay reagent (500-0006, Bio-Rad) via spectrophometric quantification (595 nm). After 
quantification of protein, 50 µg of total protein from each sample lysate were loaded to the gel 
in 5X loading buffer (10% SDS, 0.5% bromophenol blue in Tris-HCL (pH 6.8) and 10% β-
mercaptoethanol; M3148, Sigma), after protein denaturation under boiling at 950C -1000C for 10 
min.  After that, samples were centrifuged at 10600 × g for 2 mins, placed on ice and then samples 
were loaded in 12% acrylamide:bis acrylamide (29:1; 161-0156 Bio-Rad) gel (Tris-glycine SDS-
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PAGE). Electrophoresis was  performed in MINI-PROTEAN Tetra Electrophoresis System (Bio-Rad) 
at 140 V, into 1X TGS buffer (Tris-Glycine-SDS 10x; 161-0772, Bio-Rad). After that, the gel was 
transferred to an Immun-Blot® PVDF membrane with a Trans-Blot® TURBO (Bio-Rad), at 25 V, 
(1,3 A) for 10 min. When membrane transfer is completed, the membrane was blocked with 3% 
weight (w)/volume(v)) bovine serum albumin (BSA; A9647, Sigma) in PBS (1X) 0,1% volume 
(v)/volume (v) Tween 20 (PBS (1X) - 0,1% Tween - 3% BSA), for 1 h at  room temperature in 
agitation, to avoid nonspecific binding to membrane. Then the membrane was incubated with 
primary specific antibody (Rabbit anti-human xCT, ab175186- Abcam; diluted 1:1000 in PBS (1X)- 
0.1% Tween - 3% BSA for xCT at 40C with agitation, overnight. After the overnight incubation with 
primary antibody, the membrane was washed 3 times, for 5 min in agitation, with  PBS (1X) 0.1% 
(v/v) Tween 20 to remove unbound primary antibody. Then, secondary antibody was incubated 
with a primary antibody- species and class specific secondary antibody with IgG-conjugated horse 
raddish peroxidase (HRP) (anti-rabbit, 31460, from Thermo Scientific or anti-mouse 31430, 
Thermo Scientific; 1:5000 in PBS (1X)- 0.1% Tween - 3% BSA for 2 h with agitation. After 
incubation with secondary antibody, the membrane was washed 3 times, for 5 min, with PBS (1X) 
0.1% (v/v) Tween 20. To reveal peroxidase activity, ECL method was used and digital images were 
collected by using ChemiDoc  XRS system (Bio – Rad) with image lab software. β-actin was used 
as endogenous control for protein normalisation, being its levels assessed by incubating the 
membrane with anti-β-actin (A5441, Sigma Aldrich) 1:5000  in  3% (w/v) BSA in PBS1x, 1% (v/v) 
Tween 20), overnight at 40C. The intensity of each band was measured using Image J software.  
 
3.4 Transfection 
Transfection is the process of deliberately introducing naked or purified nucleic acids into 
eukaryotic cells. Transfection can be mediated by cationic liposomes that will fuse with the cell 
membrane and delivering the plasmid. 
In order to assess the role of xCT in pancreatic cancer chemoresistance QGP-1 and BON-1 cell 
lines were transfected with SLC7A11 gene coding sequence, Homo species (Genscript) in core 
plasmid pcDNA3.1/C-(k)DYK , by using the cationic liposome LipofectamineTM  2000. The Mock 
variant was transfected with the empty core plasmid pcDNA 3.1+/ C-(k)DYK. 
In the same way, the production of  BRAF, KRAS or NRAS mutated variants of  BON-1 cell line was 
performed by transfecting cells  with plasmid of BRAF (PECFP V600E), KRAS (PECFP G112V),  NRAS 
(PECEP C161R) and Mock (PECEP C3), by using the cationic liposome LipofectamineTM  2000. 
For that purpose, each cell line was cultured in a 25 cm2 cell culture T-flask, until 80% confluence. 
For each flask, 1 µg of plasmid of different variant was diluted into 500 µL of serum free 
Dulbecco’s Modified Essential Medium/Nutrient mixture F- 12 (Ham) 1x for BON-1 cell line and 
Roswell Park Memorial Institute (RPMI) 1640 Medium 1x for QGP-1 cell line. Then 20 µL of 
Lipofectamine™ 2000 were also diluted into 500 µL of serum free specific medium for T-flask. 
After that, both suspensions were incubated at room temperature for 5 min and then the two 
suspensions were mixed and again incubated at room temperature, for 20 minutes, in order to 
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form plasmid: Lipofectamine™ 2000 complexes. Finally, the complexes (1 mL) were added into 
each T-flask, replacing the culture medium. After incubation for 4-6 h, at 370C, in a humidified 5% 
CO2 environment, 2 mL of complete culture medium was added to each T-flask. 
After transfection, transfected cells were selected through continuous supplementation of 
Geneticin (10131027, Invitrogen) to the medium. With an interval of one week, the concentration 
of selective antibiotic was decreased, order of last concentration that was maintained: 1 mg/mL, 
500 µg/mL, 100 µg/mL. 
 
3.5 Immunofluorescence   
Immunofluorescence is a widely used technique that depends on the use of antibodies 
conjugated with fluorescent dye known as fluorophores or fluorochromes (eg 
fluorescein isothiocyanate- FITC) to detect a specific target antigen, under a fluorescent 
microscope. In this thesis framework, we performed an indirect method of immunofluorescence 
where the primary antibody binds to the antigen, followed by the secondary antibody, 
conjugated with a fluorophore, against the specific isotype of the primary antibody.172 
To investigate the effect of cysteine, cisplatin and sulfasalazine in xCT expression, cells were 
cultured in 8 well glass plate. After 16 h of experimental conditions, cells were fixed with 200 μL 
of 4% of paraformaldehyde (104003, Merck Millipore), incubate for 15 min at RT. Then cells were 
washed with PBS (1X) and incubated with 50 mM of NH4Cl in PBS (1X) 10 min at RT. To block and 
permeabilize the cells, PBS 1X – BSA 0.5%- 0.1 % saponin was used during 15 min at RT. After 
that, cells were incubated with the primary antibody (ab131429-Abcam; Rabbit anti-human xCT) 
diluted in PBS(1X)- 0,5% BSA -0,1% saponin ( 1:100) for 30 min. Cells were rinsed with PBS 1X – 
BSA 0.5%- 0.1 % saponin and incubated with the secondary antibody conjugated with Alexa Fluor® 
488 anti-rabbit (A-11034, Invitrogen)  during 2 h at RT. To confirm the specificity of secondary 
antibody, a negative control was used (control without primary antibody) incubated with 
secondary antibody. Then, cells were washed again with in PBS(1X)- 0,5% BSA -0,1% saponin 3 
times. After that, the slides were mounted in VECTASHIELD media containing DAPI (4′-6-
diamidino-2-phenylindole) (H1200, Vector Labs). Then, the fluorescence sign was analysed by 
standard fluorescence microscopy using a Zeiss Imajer.Z1 AX10 microscope.  
 
3.6 Statistical analysis  
For all experiments, statistical analyses were performed in GraphPad Prism 5.0 software 
(www.graphpad.com). Data is presented as the mean ± SD. Assays were performed with, at least, 
3 replicates per experimental condition. For comparisons of two groups, two-tailed unpaired T-
test was used. For comparison of more than two groups, One-way and Two-way analysis of 
variance (ANOVA) with Tukey’s multiple comparisons post hoc test were used. Statistical 




4.  Results 
 
4.1 Cisplatin induces cell death in BON-1 but not in QGP-1 cell line. 
To reveal the effect of cysteine, cisplatin and combination of cysteine and cisplatin in PNETs cell 
lines, we performed cell death analysis by flow cytometry. 
Results have shown that in BON-1 cells, with 16 h of experimental conditions, no differences were 
found upon cysteine exposure. Moreover, we also observed significant increased cell death levels 
upon exposure to cisplatin and cisplatin plus cysteine, in comparison to control and cysteine 
conditions (figure 4.1 A). 
In QGP-1 cells, with 16 h of experimental conditions, no differences were found upon exposure 
of cysteine, cisplatin and combination of cisplatin plus cysteine (figure 4.1B) 
 
 
Figure 4.1- The effect of cysteine, cisplatin and cysteine plus cisplatin, in BON-1 and QGP-1 cell 
lines. After 16 h, cells were collected, and the percentage of cell death was evaluated by flow 
cytometry.  A. Cell death in BON-1 cell line- fold change in relation to control. B. Cell death in 
QGP-1 cell line - fold change in relation to control. Results are shown as mean ± SD *p<0.05, 
**p<0.01, ***p<0.001 (One-Way ANOVA, Tukey). (*) is the statistical significance compared to 
control, (#) shown the differences between cysteine and cisplatin 
 
4.2 Inhibition of xCT together with cysteine contributes for cisplatin resistance of BON-1 cell 
line 
At first, we confirmed that xCT was expressed in BON-1 and in QTGP-1 (figure 4.2 A). To disclose 
the effect of xCT inhibition, with sulfasalazine or erastin, and cysteine supplementation, in the 




Results have shown that in BON-1 cells, with 16 h of experimental conditions, sulfasalazine itself, 
but not erastin, significantly induced cell death. Cysteine, erastin or sulfasalazine potentiated 
cisplatin toxicity, although when cisplatin was combined with cysteine plus erastin or cysteine 
plus sulfasalazine the basal cell death levels were rescued (figure 4.2 B).  
 
 
Figure 4.2- The effect of erastin, sulfasalazine and cysteine in the response of BON-1 cell line to 
cisplatin. A. xCT protein levels, in BON-1 and QGP-1 cell lines. After collection of cells, protein 
expression levels of xCT were evaluated by western blotting. B. After 16 h, cells were collected, 
and the percentage of cell death was evaluated by flow cytometry. Results are shown as mean ± 
SD *p<0.05, **p<0.01, ***p<0.001 (one-Way ANOVA, Tukey). (*) indicates the statistical 
significance compared to control, (£)  indicates the statistical significance comparing cysteine and 
cisplatin, ($) indicates the statistical significance comparing cisplatin with cisplatin plus erastin 
and cisplatin plus sulfasalazine, (#) indicates the statistical significance comparing  cisplatin with  
cisplatin plus erastin and cisplatin plus erastin plus cysteine, (&) indicates the statistical 









4.3 Sulfasalazine combined with cysteine and cisplatin stimulates the expression of xCT  
To address the effect of cysteine, cisplatin and sulfasalazine, in xCT expression, we performed an 
immunofluorescence assay. 
Through immunofluorescence analysis, with 16 h of experimental conditions in BON-1 cell, 
results showed a slightly decrease in xCT levels upon exposure of cisplatin (figure 4.3B) 
All the conditions with sulfasalazine decreased the expression of xCT, except when it was 
combined with cysteine and cisplatin (figure 4.4B) 
 
Figure 4.3- Cysteine, cisplatin, cysteine combined with cisplatin do not affect xCT protein levels, 
in BON-1 cell lines. After 16 h of conditions exposure, the protein level of xCT were analysed. A. 
Fluorescence microscopy (magnification 400 x). Nuclei were stained with DAPI (blue). B. 
Immunofluorescence quantification was done using Image J software in BON-1 cell line. Results 




     
 
Figure 4.4- The effect of cysteine, cisplatin, cysteine combined with cisplatin and sulfasalazine 
in xCT protein levels, in BON-1 cell lines. After 16 h of condition exposure, the protein levels of 
xCT were analysed. A. Fluorescence microscopy (magnification 400 x). Nuclei were stained with 
DAPI (blue). B. Immunofluorescence quantification using Image J software in BON-1 cell line. 




4.4   SeChry, but not SeChry encapsulated and functionalised with folate (SeChry@PUREG4-FA), 
induces cell death in PNETs cell lines 
In order to determine the effect of seleno-Chrysin (SeChry), in BON-1 cell line, cells were exposed 
to free SeChry and SeChry encapsulated and functionalised with folate (SeChry@PUREG4-FA). A 
cell death quantification was performed by flow cytometry. 
Result have shown that in BON-1, increased cell death levels were observed upon exposure of 
SeChry, whereas we did not observe any significant differences with SeChry@PUREG4-FA 
exposure in relation to control (figure 4.5)  
 
 
Figure 4.5   The effect of SeChry and SeChry@PUREG4-FA in BON-1 cell line.  After 24 h of exposure, 
cells were collected and the percentage of cell death in BON-1 cell line was evaluated by flow 
cytometry.   
 
4.5 Buthionine sulfoximine encapsulated and functionalised with folate (BSO@PUREG4-FA) 
induces cell death in PNETs cell lines  
In order to assess the effect of BSO in PNETs in the reversion of cisplatin resistance, cells were 
exposed to BSO@PUREG4-FA alone or combined with cysteine and/or cisplatin. Cell death was 
measured by flow cytometry. 
Results have shown that BSO@PUREG4-FA induces cell death in BON-1 and QGP-1 cells, 













































Figure 4.6 The effect of BSO@PUREG4-FA combined with cysteine and cisplatin in PNETs cells 
(BON-1 & QGP-1 cell lines).  After 16h of experimental conditions, cells were collected to perform 
the cell death analysis by flow cytometry. 
 
4.6 Failure in the transfection of BON-1 cell line with NRAS, KRAS and BRAF mutated variants 
(BRAF- V600E, KRAS-G112V, NRAS-C161R) 
We observed no alteration in the levels of phosphor-Erk (pErk), meaning that MAPK pathways 
was not altered in BON-1 cells transfected with NRAS, KRAS and BRAF mutated variants. A 
possible explanation is the fact that this cell line is already mutated for NRAS- Q61R, being the 
increased stimulation of MAPK pathway a phenomenon incompatible with cell survival which 






Figure 4.7 p-Erk levels indicate that MAPK pathway has a lower, but non- significant, flow in 
transfected cells. After collection of BON-1 cells selected with Geneticin (G418), protein 
expression level of p-Erk was evaluated. A. Western Blot membrane, β-actin was used for 
normalization. B. western blot quantification through Image j. 
 
 
4.7 Failure in the overexpression of xCT. 
Due to technical problems, we were not able to get positive transfected cell clones 
overexpressing xCT. In ana attempt to solve the problem, assays co-overexpressing xCT and its 
partner 4F2hc (SLC3A2) will be performed in the future, since the xCT stabilization and insertion 








































































Pancreatic neuroendocrine tumour (PNETs) is one of the rare tumours with a rising incidence day 
by day. Metabolic reprogramming nowadays has been recognized as a hallmark of cancer which 
causes a molecular remodelling not only in cancer cells but also in non-cancerous cells, since they 
share the same microenvironment.174   The major significance of metabolic reprogramming is to 
supply energy for proliferation and maintain the redox balance in tumour cells, protecting them 
against the oxidative stress. Collecting studies present that metabolic reprogramming is being 
linked to mechanisms of drug resistance in cancer and a rapid development of new strategies of 
anticancer drug is needed to overcome the chemoresistance.175 
Chemoresistance is a complex framework with  multiple mechanisms which is influenced by the 
microenvironment as well as by the biology of the tumour.176  In this context, GSH acts as a 
contributing factor by interacting with chemotherapeutic drugs and its depletion is exhibited as 
an effective approach in the sensitization of various types  of cancer.177,178,179 GSH directly targets 
ROS, being the most important ROS scavenging system. Cysteine is fundamental as a rate limiting 
substrate and the thiolic component of GSH.180,181,182 
 
Cisplatin induces cell death in BON-1 but not in QGP-1 cell line. 
The effectiveness of drugs is based not just on their capacity to induce DNA damage but also on 
the cells capacity to distinguish and respond to DNA damage. Following DNA damage, cells 
possibly will either repair the damage and re-enter the cell cycle or on the off chance the cells 
cannot fix the damage and proceed to die.183 
The platinum-based compound cisplatin is a chemotherapeutic compound generally utilized to 
treat cancer, which acts principally by means of DNA damage, directly through the formation of 
adducts or indirectly through the generation of ROS, and ensuing induction of apoptotic 
programs.180,184  The antineoplastic pathway of cisplatin possibly will activate several equivalent 
pathways, leading to apoptosis and cell cycle arrest, based on treatment conditions, types of cells 
or concentration.177 
To access the influence of cysteine in cisplatin induced cell death in PNETs cell lines, we exposed 
cancer cells to these compounds in separate and in combination. In extended exposure time (16 
h), cisplatin induced significant cell death in BON-1 cell line but not in QGP-1 cell line (figure 4.1).  
The presence of cysteine did not interfere with the effect of cisplatin. 
Our team already found that cysteine was able to inhibit the effect of platinum salts in ovarian 
cancer, but in PNETs cell lines we did not see cysteine as a cell protector or as capable of 
overcoming platinum drugs effect. Recent studies showed that members of the oxaliplatin family, 
such as cisplatin and carboplatin, exhibit cytotoxicity in a broader spectrum in different cancer 
treatment such as   colon, pancreas, breast, prostate and melanoma.185,186,187 The platinum-
containing drug cisplatin  combined with capecitabine in PNETs response rates are approximately 
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30%. 188,189 In melanoma, cisplatin is the most commonly used. 190 Cisplatin-DNA adducts lead to 
a conformational change of the DNA, permitting protein binding of molecules including high 
mobility group domains, which ultimately impairs DNA replication and transcription.191,192   As 
mentioned, cisplatin induces generation of ROS, that consequently leads to decreased GSH and 
ultimately causes cell death.180,184  Our results suggest that BON-1 cells may not rely efficiently on 
thiols to overcome cisplatin effects at least on the culture conditions and cysteine concentration 
we tested.  
 
xCT plays a role in cisplatin resistance of BON-1 cell line 
GSH molecule consist of cysteine, glutamic acid and glycine residues which plays an important 
role for the maintenance of intercellular redox balance and detoxification. Consequently, GSH 
levels show a positive correlation with chemoresistance.193 Cysteine is principally obtained from 
extracellular environment by system xc−, having a role as a raw material of intercellular GSH 
synthesis, closely related to the expression and function of xCT.105,194 Recent studies have 
suggested that xCT expression is associated with the development of pre-neoplastic lesions, 
cancer, poor prognosis and chemoresistance.195,106 The greater portion of the extracellular 
cysteine is oxidized to cystine which is responsible for up taking cysteine positively.196 Recent 
studies exhibit evidence for the presence of specific transporters for cysteine.197 In addition, 
extracellular breakdown of glutathione produces glutamate, glycine, and cysteine discretely, 
which are again transported into the cell. Accumulating evidence recommended the existence of 
transporters capable of cysteine-specific uptake.198,199 The role of xCT, a cystine transport system, 
causes increased levesl of GSH, involved in the process of chemoresistance.  But the inhibition of 
xCT function also interferes with its expression. Sulfasalazine and erastin are well known 
inhibitors of this transport system.108,109,110 
To reveal the modulation of xCT expression, with cysteine, cisplatin together with sulfasalazine 
and erastin, which contribute to cisplatin resistance in BON-1 cell lines, we performed cell death 
assay. For xCT transporter, by flow cytometry analysis, we observed in BON-1 cell lines that 
sulfasalazine itself decreases the expression of xCT (figure 4.4 B). As shown in the present paper, 
xCT expression affects the progression of tumour and Sulfasalazine, inhibitor of xCT, increased 
cellular oxidative stress,200   that ultimately reduces the GSH concentration (figure 4.4 B). This can 
be explained by the interconnection between the regulatory mechanisms controlling the 
expression of xCT and other cystine/cysteine transporters, such as EAAT3, which 
expression/function regulates the mTOR activity that will control ATF4 action on xCT expression. 
201 Since, EAAT3 is itself regulated by mTOR,202 a feedback positive mechanism can be activated 
upon xCT inhibition, in which a loop of interactivation between mTOR and EAAT3 expression is 
exacerbated (FIGURE 5). 
Interestingly, cisplatin induced a significant decrease in xCT expression (figure 4.3 B), which 
makes a link between the putative ferroptotic cell death induced by cisplatin, since xCT is 
considered an inhibitor of ferroptosis 118 and the use of inhibitors, such as erastin, stimulates 
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ferroptosis.203,118 This is supported by our results showing that cells exposed to cisplatin plus 
sulfasalazine or erastin present higher levels of cell death (figure 4.2 B), as it was already 
observed in other cancer contexts.204  Furthermore,  when cisplatin was combined with cysteine 
plus erastin or cysteine plus sulfasalazine a decrease in cell death was shown (figure 4.2 B). This 
phenomenon could be explained by substantial amounts of cysteine to be handled by cancer 
cells, in order to be taken up to produce enough GSH and abrogate cisplatin toxicity.197,205 
According to this, cysteine was able to rescue xCT expression, in cells exposed to the combination 
of sulfasalazine, cisplatin and cysteine (figure 4.4). As previously mentioned, xCT expression is 
induced by oxidative stress effectors, as hydrogen peroxide and sodium arsenite, ultimately leads 
to increased GSH production.206 Therefore, upon drugs induced oxidative stress, cysteine is 
needed as a precursor of GSH, that is why the mechanisms regulating the expression of Xct, as 
mentioned before, involving EAAT3, a cysteine specific transporter, can act on the direction of 
increasing cysteine uptake.207 
It is known that cysteine is necessary for the maintenance of cellular homeostasis and survival of 
cancer cells. 208,209,181 Cysteine, besides being a precursor of GSH, is used for the production of 
amino acid taurine, having a role in mitochondrial function and also in the control of cellular 
osmolarity, hydrogen sulphide (H2S) production, iron-sulfur clusters formation in cell respiration 
and also acts as a co enzyme.210,211  Cysteine uptake can be done by xCT transporter, metabolized 
in the mitochondria via CBS, CSE (dependent on its translocation from the cytosol that is 
described under stress conditions) and MpST conjugate with CAT activity (already located in the 
mitochondria), associated with H2S and ATP production.212,213 
 
In such manner, our results suggested that system xc− antiporter (sulfasalazine) can reduce 
mitochondrial dysfunction-enhanced cisplatin resistance, signifying that higher intracellular GSH 
levels caused by the system xc− antiporter might contribute to chemoresistance.214 
Our results pave new research paths in order to know in depth the role of cysteine bioavailability, 
mediated by its transporters (eg xCT), in platinum salts- induced cell death and in the definition 
of new therapeutic strategies (figure 5). However, the actual occurrence of ferroptosis in our 





FIGURE 5. Cooperation between different cystine/cysteine transporters ensures 
chemoresistance. A. The interconnection between the regulatory mechanisms controlling the 
expression of xCT and other cystine/cysteine transporters, such as EAAT3, which function 
regulates the mTOR activity and xCT expression, through the action of ATF4.201 EAAT3 is itself 
regulated by mTOR.202 B. Upon xCT inhibition, a feedback loop is activated switch on 
interstimulation of mTOR and EAAT3, enhancing EAAT3 expression and cysteine uptake to sustain 



































































SeChry, but not SeChry@PUREG4-FA, induces cell death in PNETs cell lines 
Selenium (Se) compounds in cancer research over last four decades have received attention as 
anticancer agents due to their pro-oxidant properties at higher levels.215,216 Normally, inorganic 
Se compounds exert a lower cancer therapeutic window, inducing higher systemic toxicity and 
higher metastatic burden. On the other hand, organic selenium compounds are a vast group of 
chemically diverse nucleophilic molecules, having significant anti-tumour activity accompanied 
by higher ability to prevent metastasis and lower systemic toxicity.217,218 SeChry is an 
organoselenium compound, which has become a promising candidate in cancer therapeutics, 
exerting an anti-tumoral effect.215 It is known that by inducing oxidative stress in cancer cells via 
redox modulation provides a new therapeutic window for anticancer therapy.219 Organoselenium  
compounds act as a redox modulators, exhibiting a higher selectivity and sensitivity in cancer 
cells;215,216,220 and they have been considered as xCT inhibitors.127,87  Based on the antitumoral 
effect of selenium- chrysin (SeChry), our third aim focused on the effect of new nanoformulations 
in order to disturb cysteine uptake by using Sechry. To establish our objectives, we conducted a 
cell death assay by using free SeChry and targeted delivery SeChry using nanoparticles 
functionalised with folate, SeChry@PUREG4-FA, in BON-1 cell line. Results have shown that in 
BON-1, increased cell death levels were observed upon exposure to SeChry but not to 
SeChry@PUREG4-FA (figure 4.5). This cell death conducted by SeChry could be explained by the 
newly recognized pro-oxidant role of selenated-compounds, which is based on ROS generation, 
oxidation of protein, thiols and direct or indirect DNA binding, ultimately leading to apoptotic cell 
death.215 
The lack of cell death with SeChry@PUREG4-FA exposure can be related to the low expression of 
the folate receptor. The evaluation of folate receptor expression must be addressed in our cancer 
cell models. However, some studies have pointed the neuroendocrine tumours as suitable for 
the therapies using folate functionalised particles for targeted therapy.221 
 
Buthionine sulfoximine encapsulated and functionalised with folate (BSO@PUREG4-FA) induces 
cell death in PNETs cells 
Buthionine sulfoximine  (BSO) a synthetic amino acid, irreversibly inhibits the γ-glutamyl-cysteine 
synthetase, which catalyses the rate limiting step of GSH biosynthesis.222   Increased GSH also has 
an association with reduced drugs sensitivity of tumour cells due to acquired or intrinsic 
resistance of some anticancer drugs, specially platinum salts.223,224By depleting the GSH 
synthesis, since it plays an important role in protecting cells against oxidative stress, ultimately it 
will result in free- radical induced apoptosis.225  
To reveal the effect of disturbing GSH synthesis (BSO@PUREG4-FA) in the response to cisplatin, 
we conducted a cell death assay in PNETs cell lines. In BON-1 and QGP-1 cells, significant 
increased cell death levels were induced by in BSO@PUREG4-FA compared to control (figure 4.6). 
The combination of BSO@PUREG4-FA, cisplatin and cysteine also induced a significant increase in 
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cell death in relation to cisplatin and cysteine alone. Cysteine was not able to reduce 
BSO@PUREG4-FA and cisplatin toxicity (figure 4.6), suggesting that BSO was able to inhibit GSH 
synthesis having no room for cysteine intervention in order to enhance the levels of GSH and 
consequently the resistance to cisplatin. Similar results have been observed by our team in an 
ovarian cancer model.226 
The cell death conducted by BSO@PUREG4-FA in PNETs cell lines could be explained by delivering 
BSO more efficiently to cancer cells allowing the decrease in the concentration of BSO applied. 
Platinum salts such as cisplatin respond quickly with nucleophilic sulfur-containing molecules, in 
this way a higher concentration of GSH will be able to capture cisplatin. By diminishing the pool 























6. Conclusions   
The limitation of the success of systemic anticancer therapy has been chemoresistance, 
decreasing overall survival. This problem is obvious after using chemotherapy for more than half 
a century and keeps on being a considerable issue in the present time of molecularly targeted 
drugs and personalized medicine. So, new targeted therapy can be generated to disclose what 
are the phenomena beyond the mechanism of chemoresistance. 
Pancreatic Neuroendocrine tumours (PNETs) are a rare heterogenous group of slow growing 
tumours. The chemoresistance behaviour of these tumours depends on a set of multiple 
mechanisms, specially the availability of chemotherapy agents in which ROS-scavenging systems 
act via increasing levels of GSH. To understand the cysteine driven molecular pathway in cancer 
cell resistance, research works have been investigating the role of cysteine transporters, so that 
they can be able to design new therapeutic strategies to fight cancer progression. The main 
objective of our work allowed to reveal the role of xCT transporter and the role of cysteine in 
PNETs cell line resistance. This cell line showing different response patterns in cysteine 
transporters activity helped to reveal the differences of the transporter in chemoresistance 
mechanism. It also showed that beside xCT transporter other cysteine transporter such as EAAT3 
also appeared to be involved in the dynamics of chemoresistance mechanism. 
This work was also important to undercover the effect of new nanoformulations in order to 
disturb cysteine uptake by using SeChry and to inhibit GSH synthesis by using BSO in PNETs cell 
lines. SeChry, but not SeChry@PUREG4-FA, induced cell death in BON-1 cell lines. SeChry 
cytotoxicity can be selective for cancer cells and this was taken in consideration in our new 
strategy by using SeChry@PUREG4-FA, however the assay was not successful and new markers 
for targeted delivery must be investigated in PNETs.  
BSO@PUREG4-FA induced cell death in combination with platinum salts in PNETs cell lines. 
Possibly, the use of folate functionalised particles will help to bypass the critical step in the non-
specific delivery of BSO to non-cancer cell.  The targeted BSO delivery to cancer cells can be 
explored as a novel strategy in cancer therapeutics. 
Moreover, more assays with cancer and non-cancer cells must be done in order to determine if 










7. Future perspectives 
Our study paved the path for some new cancer reaserch lines in the context of cancer metabolism 
and chemoresistance in PNETs. So as future perspectives, it would be interesting: 
• To study in depth the effect of xCT transporter, upon SeChry and cisplatin exposure. 
• To evaluate the EAAT3 transporters modulation, upon exposure of sulfasalazine and 
erastin, xCT inhibitors. 
• To evaluated the metabolic modulation and response to therapy in cells co-
overexpressing xCT and 4F2hc. 
• To reveal the cytotoxic effect of SeChry in non-malignant cell lines. 
• To verify the effect of xCT and EAAT3 transporter modulation upon exposure of cysteine 
and  cisplatin. 
• To reveal the expression of enzymes involved in cysteine metabolism and glutathione 
synthesis in PNETs sections by immunohistochemistry. 
• To address the cysteine metabolism in different KRAS/BRAF genetic backgrounds, 
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Solutions used in the experimental work 
 
PBS 10X (pH 7.4-7.6) 
1 L= 80 g NaCl (1,37 M) (106404, Merck) 
         2 g KH2PO4 (14,7 mM) (104873, Merck) 
          11,1 g Na2HPO4 (78,1 mM) (S-0876, Sigma) 




PBS(1X) – 0,1% (v/v) Tween 20 
1 L= 1X PBS 1 L  
1 mL Tween 20 (20605, USB) 
 
 
PBS(1X) - 0,1% (v/v) Tween 20 - 3% (w/v) BSA 
PBS 1X – 0,1% (v/v) Tween 100 mL  
3 g BSA (A9647, Sigma) 
 
 
PBS(1X) – 0,5% (w/v) BSA – 0,1% (w/v) saponin 
For100 mL 
 100 Ml PBS1X 
 0,5 g BSA (A9647, Sigma) 





 Propidium Iodide (PI) solution (50 μg/mL) 
For 50 mL: 
  1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in 1X PBS)   
  49 mL 1X PBS 
 
 
Annexin binding buffer  
1X 0.01 M Hepes (pH 7.4) (391333, Millipore)  
 0.14 M NaCl (106404, Merck)  




For 500mL:  
7,5 g glycine (US16407, USB) 
 1,5 g Trizma-base (T-8524, Sigma) 
 100 mL Metanol (107018, Merck) 
 0,5mL 10% SDS (V6551, Promega) 
 ddH2O to 400 mL 
 
 
5X SDS gel loading buffer 
250 mM Tris HCl (pH 6,8) (0,5M 161-0799, Bio-Rad) 
10% SDS (V6551, Promega) 
0,5% bromophenol blue 




PBS(1X) – 0,1% (w/v) BSA 
For 100 Ml 
 PBS 1X 100 mL 





For 10 mL 
 20 mM Tris-HCl pH 7,5 
 150 mM NaCl (106404, Merck) 
 5 mM KCl (104936, Merck) 
 5 mM MgCl2 (M-8266, Sigma) 
 1% Triton X-100 (T8787, Sigma) 
 1 Complete Mini, EDTA-free Protease Inhibitor 
Cocktail Tablet (11836170001, Roche) 
 1 mM Orthovanadate (Na3VO4) 
 1 mM Sodium fluoride (NaF) (201154, Sigma) 
 ddH2O to 10 mL 
